Nanogen awarded six patents for use of biomarkers in diabetes, Alzheimer's disease

By Lisa Kerner

Charlotte, N.C., Aug. 24 - The U.S. Patent and Trademark Office issued six patents to Nanogen, Inc. for inventions related to diabetes and Alzheimer's disease and biomarkers, according to a news release.

Nanogen said three patents cover the use of mass spectrometry and time-of-flight detection to identify various biomarkers such as those associated with metabolic Syndrome X and related conditions. Symptoms of early stage Syndrome X include insulin resistance, abnormal blood lipids and high blood pressure; later stages lead to diabetes, kidney failure and heart failure.

Two patents that relate to the use of mass spectrometry and time-of-flight detection measures clarify biopolymer markers associated with both Alzheimer's disease and Syndrome X, according to the release.

Nanogen's sixth patent claims a method for identifying which patients suffering from mild cognitive impairment are likely to develop Alzheimer's disease. The method detects human glutamine synthetase, by immunoassay of bodily fluids.

Nanogen is a San Diego-based diagnostics product company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.